S. 5571 · 119th Congress
A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
What it does
The Congressional Research Service hasn’t published a summary of this bill yet. Summaries usually follow within a few weeks of introduction.
Roll call votes
No recorded roll call votes on this bill. Most bills never get one; many pass by voice vote or unanimous consent, or stay in committee.
Latest action
Sep 28, 2026 · Read twice and referred to the Committee on Finance.